PDLI  Pdl Biopharma Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

-0.02 (-0.85%)

Growth Price

Undervalued by 408.41%

Stability Price

Undervalued by 290.41%

Company Metrics

  • P/E 2.2
  • P/S 1.36
  • P/B 0.52
  • EPS 1.06
  • Cash ROIC 18.83%
  • Cash Ratio 6.00
  • Dividend 0.2 / 8.89%
  • Avg. Vol. 2.72M
  • Shares 165.54M
  • Market Cap. 385.71M

Company Description

PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. Its Queen et al. patents primarily cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized a... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Can PDL BioPharma Be a Top Choice for Value Investors?
Yahoo Finance - 20 hours ago
If we focus on the stock's long-term PE trend, the current level puts PDL BioPharma's current PE ratio below its midpoint over the past five years, with the number having fallen rapidly over the past few months.
Here's Why PDL BioPharma Inc. Imploded and Fell 32% in November
Motley Fool - Dec 2, 2016
Shares of PDL BioPharma (NASDAQ:PDLI), a biotech royalty company, imploded in November and lost 32% of their value according to data from S&P Global Market Intelligence.
Is PDL BioPharma Inc (PDLI) Going to Burn These Hedge Funds? - Insider Monkey (blog)
Why PDL BioPharma Inc. Is Down 14.8% Today
Motley Fool - Nov 23, 2016
Shares in PDL BioPharma (NASDAQ:PDLI) are tumbling 14.8% at 12:30 p.m. EST Wednesday after management closed on a $150 million convertible notes offering and Eli Lilly & Co.
Company Update (NASDAQ:PDLI): Here's Why PDL BioPharma Inc Shares Are Slumping ... - Smarter Analyst
Can PDL BioPharma, Inc. Turn Things Around?
Motley Fool - Oct 28, 2016
In 18 months, PDL BioPharma, Inc. (NASDAQ:PDLI) has lost roughly half of its market cap. The slide wasn't unexpected: Investors have known for a long time that PDL BioPharma's core patents would expire at the end of 2014.
Brokerages Expect PDL BioPharma, Inc. (PDLI) to Announce $0.13 Earnings Per Share
Sports Perspectives - 23 hours ago
PDL BioPharma, Inc. (NASDAQ:PDLI) has earned a consensus broker rating score of 2.00 (Buy) from the two analysts that cover the company, Zacks Investment Research reports.
what are Analysts report about: PDL BioPharma, Inc. (NASDAQ:PDLI) - News Oracle
PDL BioPharma, Inc. (NASDAQ:PDLI) Closed the Last Trading Session at $2.35 - The Newburgh Press
PDL BioPharma Prices Public Offering of $150.0 Million of 2.75% Convertible ...
PR Newswire (press release) - Nov 17, 2016
INCLINE VILLAGE, Nev., Nov. 17, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it has agreed to sell $150.0 million aggregate principal amount of its 2.75% Convertible Senior Notes due 2021 (the Notes) in an ...
Why Lowe's Companies, Inc. (LOW), PDL BioPharma Inc (PDLI) and Mallinckrodt ... - Investorplace.com
Why PDL BioPharma Inc (NASDAQ:PDLI) Is Raising Debt - Market Exclusive
This Expected News Sent PDL BioPharma Inc. Down 17% in August
Motley Fool - Sep 7, 2016
Shares of PDL BioPharma (NASDAQ:PDLI), a royalty company in the biotech space that earns its keep by reaping the rewards of its acquired intellectual property and low overhead costs, sank 17% in August, according to data from S&P Global Market ...
PDL BioPharma, Inc. Is Off 10% in 2016, and This Is a Big Reason Why
Motley Fool - Jun 20, 2016
What: Shares of PDL BioPharma (NASDAQ:PDLI), a small-cap biotech company that invests in patents and royalty-based biotechnology and pharmaceutical assets, has lost 10% of its value so far this year, according to data from S&P Global Market ...
PDL BioPharma Issues $150.0 Million of 2.75% Convertible Senior Notes Due 2021
PR Newswire (press release) - Nov 22, 2016
INCLINE VILLAGE, Nev., Nov. 22, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today the closing of its previously announced offering of convertible senior unsecured notes due December 1, 2021 (2021 Notes).
PDL BioPharma Announces Proposed $150 Million Public Offering of New ...
PR Newswire (press release) - Nov 15, 2016
15, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of new convertible senior notes due December 1, 2021 (the ...